1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

High Turnover

Discussion in 'Becton Dickinson' started by anonymous, Apr 27, 2018 at 12:03 PM.

  1. anonymous

    anonymous Guest

    Solid company, but high turnover.
     
  2. anonymous

    anonymous Guest

    What is turnover attributed to?
     
  3. anonymous

    anonymous Guest


    You picked up an RBD from Novo who had HUGE turnover.
     
  4. anonymous

    anonymous Guest

    I worked for BD for about 5 years. Solid company with great products. Turnover in my division (Diagnostics) was minimal.
     
  5. anonymous

    anonymous Guest

    What will happen to Bard now that they are almost fully integrated into BD? Will BD lower comp plans? I'm suspecting as much, since that seems to be what happened when Care Fusion was melded into the organization.
     
  6. anonymous

    anonymous Guest

    You can bet they will. Prepare to have comp slashed, probably right after the NSM in November.
     
  7. anonymous

    anonymous Guest

    I wouldn't say BD has high turnover by any means. They have number 1 marketshare for most product lines, but their products aren't really considered sophisticated or physician preference. Reputable company, respected by customers. Bard is making the pay scale more heavily weighted towards commission. Higher risk but higher reward.